TARA: Tapering csDMARDs First vs TNF Inhibitors in Patients With RA and Very Low Disease Activity

November 8-13, 2019; Atlanta, Georgia
Similar disease flare rates with both tapering schedules, but tapering csDMARD first associated with numerically higher DMARD-free remission.
Format: Microsoft PowerPoint (.ppt)
File Size: 202 KB
Released: November 15, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Stanley B. Cohen, MD Released: December 23, 2020

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue